English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  51508670    Online Users :  844
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"jia horng kao"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 426-450 of 1180  (48 Page(s) Totally)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2021-09-04T06:11:42Z Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin Chen M.-Y.; Liu C.-H.; Chen T.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:42Z Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L.
臺大學術典藏 2021-09-04T06:11:41Z Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters Tseng T.-C.; Liu C.-J.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:41Z Peginterferon α in the treatment of chronic hepatitis B Tseng T.-C.; JIA-HORNG KAO; Chen D.-S.
臺大學術典藏 2021-09-04T06:11:40Z Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan Chen C.-L.; Yang W.-S.; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; Liu C.-J.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Chen C.-J.
臺大學術典藏 2021-09-04T06:11:40Z Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications Wu H.-L.; JIA-HORNG KAO; Chen T.-C.; Wu W.-H.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen D.-S.; Chen P.-J.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:40Z Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Chen T.-C.; Tseng T.-C.; Liu C.-H.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:39Z All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S.
臺大學術典藏 2021-09-04T06:11:39Z Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study Huang Y.-W.; Yang S.-S.; Fu S.-C.; Wang T.-C.; Hsu C.-K.; Chen D.-S.; Hu J.-T.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z HBeAg-positive chronic hepatitis B: Why do I treat my patients with pegylated interferon? JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z A pilot study of add-on oral hypoglycemic agents in treatment-na?ve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin Hsu C.-S.; Hsu S.-J.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients Wang C.-C.; Tseng T.-C.; Wang P.-C.; Lin H.H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:38Z Reduced toll-like receptor 9 expression on peripheral C D14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy Huang Y.-W.; Hsu C.-K.; Lin S.-C.; Wei S.-C.; Hu J.-T.; Chang H.-Y.; Liang C.-W.; Chen D.-S.; Chen P.-J.; Hsu P.-N.; Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:37Z Molecular mechanism and treatment of viral hepatitis-related liver fibrosis Su T.-H.; JIA-HORNG KAO; Liu C.-J.
臺大學術典藏 2021-09-04T06:11:37Z Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:37Z Triple therapy for hepatitis C virus infection in patients receiving hemodialysis Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z Risk stratification of HBV infection in Asia-Pacific region JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:36Z The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Lin S.-R.; Yang H.-C.; Kuo Y.-T.; Liu C.-J.; Yang T.-Y.; Sung K.-C.; Lin Y.-Y.; Wang H.-Y.; Wang C.-C.; Shen Y.-C.; Wu F.-Y.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.
臺大學術典藏 2021-09-04T06:11:35Z What can we learn from hepatitis B virus clinical cohorts? Lin C.-L.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:35Z Hepatitis B virus infection and metabolic syndrome: Fact or fiction? Wang C.-C.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:35Z Asunaprevir-containing regimens for the treatment of hepatitis C virus infection Yang S.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Viral hepatitis: HBV cure-can we pin our hopes on immunotherapy? Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Treating immune-tolerant Hepatitis B Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T06:11:34Z Micro-evolution of the hepatitis B virus genome in hepatitis B e-antigen-positive carriers: Comparison of genotypes B and C at various immune stages Liu C.-J.; Chen T.-C.; Chen P.-J.; Wang H.-Y.; Tseng T.-C.; Cheng H.-R.; Liu C.-H.; Chen D.-S.; JIA-HORNG KAO

Showing items 426-450 of 1180  (48 Page(s) Totally)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
View [10|25|50] records per page